Factors influencing adverse events following COVID-19 vaccination
Various novel platform technologies have been used for the development of COVID-19 vaccines. In this nested cohort study among healthcare workers in Australia and Brazil who received three different COVID-19-specific vaccines, we (a) evaluated the incidence of adverse events following immunization (AEFI); (b) compared AEFI by vaccine type, dose and country; (c) identified factors influencing the incidence of AEFI; and (d) assessed the association between reactogenicity and vaccine anti-spike IgG antibody responses. Of 1302 participants who received homologous 2-dose regimens of ChAdOx1-S (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech) or CoronaVac (Sinovac), 1219 (94%) completed vaccine reaction questionnaires. Following the first vaccine dose, the incidence of any systemic reaction was higher in ChAdOx1-S recipients (374/806, 46%) compared with BNT162b2 (55/151, 36%; p = 0.02) or CoronaVac (26/262, 10%; p < 0.001) recipients. After the second vaccine dose, the incidence of any systemic reaction was higher in BNT162b2 recipients (66/151, 44%) compared with ChAdOx1-S (164/806, 20%; p < 0.001) or CoronaVac (23/262, 9%; p < 0.001) recipients. AEFI risk was higher in younger participants, females, participants in Australia, and varied by vaccine type and dose. Prior COVID-19 did not impact the risk of AEFI. Participants in Australia compared with Brazil reported a higher incidence of any local reaction (170/231, 74% vs 222/726, 31%, p < 0.001) and any systemic reaction (171/231, 74% vs 328/726, 45%, p < 0.001), regardless of vaccine type. Following a primary course of ChAdOx1-S or CoronaVac vaccination, participants who did not report AEFI seroconverted at a similar rate to those who reported local or systemic reactions. In conclusion, we found that the incidence of AEFI was influenced by participant age and COVID-19 vaccine type, and differed between participants in Australia and Brazil.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 20(2024), 1 vom: 31. März, Seite 2323853 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Villanueva, Paola [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse events |
|---|
| Anmerkungen: |
Date Completed 07.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2024.2323853 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369355016 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369355016 | ||
| 003 | DE-627 | ||
| 005 | 20240315233523.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2024.2323853 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369355016 | ||
| 035 | |a (NLM)38445666 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Villanueva, Paola |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Factors influencing adverse events following COVID-19 vaccination |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Various novel platform technologies have been used for the development of COVID-19 vaccines. In this nested cohort study among healthcare workers in Australia and Brazil who received three different COVID-19-specific vaccines, we (a) evaluated the incidence of adverse events following immunization (AEFI); (b) compared AEFI by vaccine type, dose and country; (c) identified factors influencing the incidence of AEFI; and (d) assessed the association between reactogenicity and vaccine anti-spike IgG antibody responses. Of 1302 participants who received homologous 2-dose regimens of ChAdOx1-S (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech) or CoronaVac (Sinovac), 1219 (94%) completed vaccine reaction questionnaires. Following the first vaccine dose, the incidence of any systemic reaction was higher in ChAdOx1-S recipients (374/806, 46%) compared with BNT162b2 (55/151, 36%; p = 0.02) or CoronaVac (26/262, 10%; p < 0.001) recipients. After the second vaccine dose, the incidence of any systemic reaction was higher in BNT162b2 recipients (66/151, 44%) compared with ChAdOx1-S (164/806, 20%; p < 0.001) or CoronaVac (23/262, 9%; p < 0.001) recipients. AEFI risk was higher in younger participants, females, participants in Australia, and varied by vaccine type and dose. Prior COVID-19 did not impact the risk of AEFI. Participants in Australia compared with Brazil reported a higher incidence of any local reaction (170/231, 74% vs 222/726, 31%, p < 0.001) and any systemic reaction (171/231, 74% vs 328/726, 45%, p < 0.001), regardless of vaccine type. Following a primary course of ChAdOx1-S or CoronaVac vaccination, participants who did not report AEFI seroconverted at a similar rate to those who reported local or systemic reactions. In conclusion, we found that the incidence of AEFI was influenced by participant age and COVID-19 vaccine type, and differed between participants in Australia and Brazil | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a antibody responses | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 700 | 1 | |a McDonald, Ellie |e verfasserin |4 aut | |
| 700 | 1 | |a Croda, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Croda, Mariana Garcia |e verfasserin |4 aut | |
| 700 | 1 | |a Dalcolmo, Margareth |e verfasserin |4 aut | |
| 700 | 1 | |a Dos Santos, Glauce |e verfasserin |4 aut | |
| 700 | 1 | |a Jardim, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Lacerda, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Lynn, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Oliveira, Roberto D |e verfasserin |4 aut | |
| 700 | 1 | |a Rocha, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Sawka, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Val, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Pittet, Laure F |e verfasserin |4 aut | |
| 700 | 1 | |a Messina, Nicole L |e verfasserin |4 aut | |
| 700 | 1 | |a Curtis, Nigel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 20(2024), 1 vom: 31. März, Seite 2323853 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:1 |g day:31 |g month:03 |g pages:2323853 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2024.2323853 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 1 |b 31 |c 03 |h 2323853 | ||